InVitro International & the World's Animals Look Forward to 2026

Rhea-AI Summary

InVitro International (OTCQB: IVRO) reported 1st Quarter FY'26 sales of $182,600, down 25% year-over-year, and net income of $10,604, down 69% year-over-year. Management described the quarter as "positive" but noted stronger global regulatory and government support for in vitro testing.

The company said it remains committed to replacing animal testing with validated non-animal methods and looks forward to FY'26 second quarter developments.

Positive

• Net income of $10,604 in 1Q FY26
• Management cites increased regulatory and government support for in vitro testing

Negative

• 1Q FY26 sales fell 25% YoY to $182,600
• Net income declined 69% YoY in 1Q FY26

Placentia, California--(Newsfile Corp. - February 11, 2026) - Today, InVitro International (OTCQB: IVRO) reported 1^st Quarter FY '26 sales of $182,600, off 25% from the same period in FY '25. Net income of $10,604 fell 69% from the same period FY'25.

Chairman & CEO, W. Richard Ulmer observed: "Our first quarter financials, though positive, do not reflect the many global Regulatory/Government statements encouraging in vitro testing over the past year. That acknowledged, we cannot recall in our 40 years a time when there is more support from both citizens and Government Agencies to replace animal testing with validated non-animal test methods. We remain steadfast in our beliefs for the future & look forward to our FY'26 second Quarter."

About InVitro International, Inc.

InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology driven provider of non-animal testing methods. The Company's testing technologies are designed to produce Regulatory Agencies' approved data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.

This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update such statements.

Company Contact:
W. Richard Ulmer
Chairman and Chief Executive Officer
(800)246-8487
invitro@invitrointl.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283229

FAQ

What were InVitro International (IVRO) 1Q FY26 sales and how did they change year-over-year?

Sales were $182,600 in 1Q FY26, down 25% year-over-year. According to the company, the decline reflects quarter-over-quarter revenue weakness despite growing regulatory interest in non-animal testing.

What was InVitro International (IVRO) net income for 1Q FY26 and the YoY change?

Net income was $10,604 in 1Q FY26, a 69% decline year-over-year. According to the company, earnings remained positive but materially lower versus the same period in FY25.

How did InVitro International describe regulatory trends affecting its business in February 2026?

The company said there is increased global and government support for in vitro testing. According to the company, this support may benefit long-term adoption of validated non-animal test methods.

Does InVitro International (IVRO) expect improvements after 1Q FY26?

Management indicated optimism and is looking forward to FY'26 second quarter results. According to the company, ongoing regulatory momentum underpins its positive outlook for the coming quarter.

What should investors know about IVRO's short-term financial position after 1Q FY26?

The company remained modestly profitable but saw sharp revenue and income declines in 1Q FY26. According to the company, investors should weigh reduced sales against growing regulatory support for the market.